| Systemic Lupus Erythematosus Research | Lifetime | 51 | JP 2 | 99.70 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 38 | JP 2 | 99.78 |
| Amoebic Infections and Treatments | Lifetime | 15 | JP 1 | 99.28 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 38 | JP 2 | 99.63 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 104 | JP 2 | 99.65 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 250 | JP 4 | 99.47 |
| Lymphoma Diagnosis and Treatment | Lifetime | 186 | JP 3 | 99.40 |
| Biosimilars and Bioanalytical Methods | Lifetime | 62 | JP 2 | 98.40 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 34 | JP 11 | 98.22 |
| Immune Cell Function and Interaction | Lifetime | 898 | JP 44 | 98.89 |
| T-cell and B-cell Immunology | Lifetime | 621 | JP 24 | 98.86 |
| Parasitic Infections and Diagnostics | Lifetime | 165 | JP 4 | 98.32 |
| Vasculitis and related conditions | Lifetime | 159 | JP 5 | 98.04 |
| Salivary Gland Disorders and Functions | Lifetime | 167 | JP 10 | 97.78 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 398 | JP 24 | 97.82 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 454 | JP 43 | 97.67 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 599 | JP 16 | 97.56 |
| Systemic Sclerosis and Related Diseases | Lifetime | 324 | JP 23 | 97.49 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 430 | JP 16 | 96.31 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 259 | JP 30 | 96.41 |
| Peripheral Neuropathies and Disorders | Lifetime | 414 | JP 24 | 96.81 |
| Diagnosis and treatment of tuberculosis | Lifetime | 418 | JP 8 | 95.17 |
| Spondyloarthritis Studies and Treatments | Lifetime | 370 | JP 5 | 96.40 |
| Eosinophilic Disorders and Syndromes | Lifetime | 708 | JP 52 | 95.28 |
| Toxoplasma gondii Research Studies | Lifetime | 517 | JP 15 | 94.86 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 291 | JP 12 | 92.52 |
| Musculoskeletal synovial abnormalities and treatments | Lifetime | 900 | JP 64 | 91.16 |
| Dermatological and COVID-19 studies | Lifetime | 853 | JP 44 | 74.10 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 5 | JP 2 | 99.78 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 12 | JP 2 | 99.58 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 28 | JP 2 | 99.11 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 33 | JP 2 | 99.48 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 21 | JP 2 | 99.26 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 37 | JP 1 | 97.18 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 30 | JP 2 | 95.74 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 161 | JP 3 | 98.31 |
| T-cell and B-cell Immunology | 2021-2025 | 267 | JP 13 | 93.02 |
| Immune Cell Function and Interaction | 2021-2025 | 884 | JP 40 | 91.70 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 182 | JP 5 | 91.57 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 38 | JP 13 | 92.65 |
| Vasculitis and related conditions | 2021-2025 | 210 | JP 11 | 93.08 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 787 | JP 86 | 89.11 |
| Gastrointestinal disorders and treatments | 2021-2025 | 625 | JP 103 | 85.57 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 536 | JP 27 | 86.75 |
| Inflammasome and immune disorders | 2021-2025 | 801 | JP 13 | 83.25 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 384 | JP 41 | 83.53 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 816 | JP 35 | 82.61 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 668 | JP 53 | 79.00 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 840 | JP 17 | 79.13 |
| Salivary Gland Disorders and Functions | 2021-2025 | 684 | JP 35 | 74.17 |
| Dermatological and COVID-19 studies | 2021-2025 | 256 | JP 4 | 72.07 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 453 | JP 8 | 69.15 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 370 | JP 25 | 71.55 |
| Bone Metabolism and Diseases | 2021-2025 | 997 | JP 79 | 68.27 |